Skip to main content
IMRX logo

IMRX · Immuneering Corp

Track IMRX — free
$3.42 -0.09 (-2.43%)
Market Cap
$220.84M
Shares
64.76M
Volume · Nov 19 201.5K Avg daily vol (3M) 730.02K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.50 Open$3.46 Day$3.43–3.58 52W close$3.37–8.33 Avg vol 30d813K Short int14.6M · 22.5% of shares · 19.2d Short vol49% Last earningsJun 1, 2026 DataJul 2021–Nov 2026 Filing10-Q · Oct 29

Up next

Dec 18, 2026 Est · unconfirmed · in 4 wks

Latest documents

2026
Nov 9
Current report 8-K
Grant C. Bogle appointed Class III director

Immuneering Corporation appointed Grant C. Bogle, MBA, as a Class III Director on November 9, 2026. He will receive compensation under the company’s arrangements for non-employee directors and has not joined a board committee.

Director or officer change, or executive pay
3 source passages
On November 9, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Grant C. Bogle, MBA, to serve as a member of the Company's Board as a Class III Director. Mr. Bogle will receive compensation in accordance with the Company’s compensation arrangements for non-employee directors. Mr. Bogle has not been appointed to a committee of the Board of Directors at this time. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
MAPKeeper 301 enrollment target raised to approximately 570 patients

Immuneering raised the MAPKeeper 301 enrollment target from 510 to approximately 570 patients, ahead of schedule, keeping topline data planned for mid-2028. Net loss was $54.9 million for the nine months ended September 30, 2026, with $166.1 million in cash, cash equivalents and marketable securities. Cash is now expected to fund operations into the fourth quarter of 2028, previously into 2029.

Net loss $24.19M Diluted EPS -$0.37
Read from the MD&A section
6 source passages
In October 2026, we announced an increase in the MAPKeeper 301 enrollment target from 510 to approximately 570 patients and that enrollment was ahead of schedule. We expect to maintain the trial's topline data readout currently planned for mid-2028, with the potential to accelerate the timing of the readout. Our net loss was approximately $54.9 million for the nine months ended September 30, 2026 and approximately $56.0 million for the year ended December 31, 2025. As of September 30, 2026, we had an accumulated deficit of approximately $335.2 million and approximately $166.1 million in cash, cash equivalents and marketable securities. This update to our cash runway guidance (previously expected into 2029) reflects the anticipated cost impact, among other things, of: a longer than previously projected continuation of our ongoing Phase 1/2a clinical trial of atebimetinib in patients with advanced solid tumors; the planned increase to and acceleration of the target patient enrollment in the MAPKeeper 301 trial; and commercial readiness activities. we believe that our existing cash, cash equivalents and marketable securities as of September 30, 2026 will enable us to fund our development activities and other operations into the fourth quarter of 2028. Open the document at this passage
Oct 29
Current report 8-K
MAPKeeper 301 enrollment expands to approximately 570 patients

Immuneering said MAPKeeper 301 enrollment is ahead of schedule, expanding the Phase 3 trial to approximately 570 patients and potentially accelerating mid-2028 topline data. Cash runway guidance was updated to the fourth quarter of 2028.

Financial results
2 source passages
Enrollment is ahead of schedule for Immuneering’s Phase 3 MAPKeeper 301 trial, enabling the Company to expand the trial to approximately 570 patients and potentially accelerate its current mid-2028 topline data readout guidance. Based on cash, cash equivalents and marketable securities as of September 30, 2026, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the fourth quarter of 2028. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$66.50M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-27.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$58.23M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+63.1%
Year over year · more shares
Price change (1Y)
-51.0%
Trailing year
Short interest
22.5%
Latest settlement · 19.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Very Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −26%
below
Price vs 50-day avg −11%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 3%
near low
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −39%
trailing
YTD return −47%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+18% holders QoQ · +29 funds added
Insider flow Accumulating
Net +$89.5K over 90 days · 0% sells
Short interest Falling
22.54% of shares out · ▼ -10.6% MoM · 19.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
132 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +38%
Y/Y
Free cash flow $-45.5M
Balance sheet $128.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −60%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+18% holders QoQ · +29 funds added
Insider flow Accumulating
Net +$89.5K over 90 days · 0% sells
Short interest Falling
22.54% of shares out · ▼ -10.6% MoM · 19.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
132 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 3% Range high $8
vs 200-day avg -26% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Atebimetinib-treated patients in ctDNA analysis 123 second quarter 2026 —
Evaluable patients weight stable or gaining weight at 3 months (atebimetinib + mGnP) 84% second quarter 2026 —
Phase 2a first-line pancreatic cancer patients treated with atebimetinib + mGnP 55 second quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMRX
Immuneering Corp
this stock
$220.84M -46.8% -100.0% — 22.5%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
132
% held
54.1%
Net QoQ
+581.6K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
99
View
Short & Settlement
Short Interest Falling
Shares short
14.6M
Days to cover
19.2d
Change
-1.7M sh
View
Short Volume
Short vol %
49%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
5.0K
Value
$20.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
47.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$89.5K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-56.0M
EPS diluted
$-1.27
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
15

Immuneering Corporation appointed Grant C. Bogle, MBA, as a Class III Director on November 9, 2026. He will receive compensation under the company’s arrangements for non-employee directors and has not joined a board committee.

View
Proposed Sales
Value
$136.1K
Shares
14.0K
Filed
Sep 23, 2025
View
Exempt Offerings
Offering
$25.0M
Filed
Sep 9, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Immuneering Reports Third Quarter…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
IMRX -7.7% -6.4% -39.3% -6.5% -46.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -3.8% -0.9% -35.9% -3.2% -53.9%
Key facts CIK 1790340 CUSIP 45254E107 13F (30d) 134 filings 122 filers Visit website Investor relations